Global Benign Prostatic Hyperplasia (BPH) Drugs Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Benign Prostatic Hyperplasia (BPH) Drugs market size is predicted to grow from US$ 3478 million in 2025 to US$ 4256 million in 2031; it is expected to grow at a CAGR of 3.4% from 2025 to 2031.
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
LP Information, Inc. (LPI) ' newest research report, the “Benign Prostatic Hyperplasia (BPH) Drugs Industry Forecast” looks at past sales and reviews total world Benign Prostatic Hyperplasia (BPH) Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hyperplasia (BPH) Drugs sales for 2025 through 2031. With Benign Prostatic Hyperplasia (BPH) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hyperplasia (BPH) Drugs industry.
This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hyperplasia (BPH) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hyperplasia (BPH) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Benign Prostatic Hyperplasia (BPH) Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hyperplasia (BPH) Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hyperplasia (BPH) Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Benign Prostatic Hyperplasia (BPH) Drugs market?
What factors are driving Benign Prostatic Hyperplasia (BPH) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Benign Prostatic Hyperplasia (BPH) Drugs market opportunities vary by end market size?
How does Benign Prostatic Hyperplasia (BPH) Drugs break out by Type, by Application?
The global Benign Prostatic Hyperplasia (BPH) Drugs market size is predicted to grow from US$ 3478 million in 2025 to US$ 4256 million in 2031; it is expected to grow at a CAGR of 3.4% from 2025 to 2031.
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
LP Information, Inc. (LPI) ' newest research report, the “Benign Prostatic Hyperplasia (BPH) Drugs Industry Forecast” looks at past sales and reviews total world Benign Prostatic Hyperplasia (BPH) Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hyperplasia (BPH) Drugs sales for 2025 through 2031. With Benign Prostatic Hyperplasia (BPH) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hyperplasia (BPH) Drugs industry.
This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hyperplasia (BPH) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hyperplasia (BPH) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Benign Prostatic Hyperplasia (BPH) Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hyperplasia (BPH) Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hyperplasia (BPH) Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Alpha-Blocker
- Phosphodiesterase Type-5 Inhibitors
- Others
- Hospitals
- Drugstores
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Eli Lilly
- GlaxoSmithKline
- Astellas Pharma
- Sanofi
- Pfizer
- Abbott
- Allergan
- TEVA
- Mylan
- Novartis
- Merck
What is the 10-year outlook for the global Benign Prostatic Hyperplasia (BPH) Drugs market?
What factors are driving Benign Prostatic Hyperplasia (BPH) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Benign Prostatic Hyperplasia (BPH) Drugs market opportunities vary by end market size?
How does Benign Prostatic Hyperplasia (BPH) Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Country/Region, 2020, 2024 & 2031
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
2.2.1 Alpha-Blocker
2.2.2 Phosphodiesterase Type-5 Inhibitors
2.2.3 Others
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2020-2025)
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Drugstores
2.4.3 Others
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
2.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2025)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company
3.4 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Location Distribution
3.4.2 Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
4.4 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
4.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
4.6 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
5 AMERICAS
5.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025)
5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025)
5.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
5.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2020-2025)
6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2020-2025)
6.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
6.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Country
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025)
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs by Country
8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
10.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
10.4 Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
11.3 Benign Prostatic Hyperplasia (BPH) Drugs Customer
12 WORLD FORECAST REVIEW FOR BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY GEOGRAPHIC REGION
12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Region
12.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Region (2026-2031)
12.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type (2026-2031)
12.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Eli Lilly
13.1.1 Eli Lilly Company Information
13.1.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Eli Lilly Main Business Overview
13.1.5 Eli Lilly Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Astellas Pharma
13.3.1 Astellas Pharma Company Information
13.3.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Astellas Pharma Main Business Overview
13.3.5 Astellas Pharma Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 Abbott
13.6.1 Abbott Company Information
13.6.2 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Abbott Main Business Overview
13.6.5 Abbott Latest Developments
13.7 Allergan
13.7.1 Allergan Company Information
13.7.2 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Allergan Main Business Overview
13.7.5 Allergan Latest Developments
13.8 TEVA
13.8.1 TEVA Company Information
13.8.2 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 TEVA Main Business Overview
13.8.5 TEVA Latest Developments
13.9 Mylan
13.9.1 Mylan Company Information
13.9.2 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Mylan Main Business Overview
13.9.5 Mylan Latest Developments
13.10 Novartis
13.10.1 Novartis Company Information
13.10.2 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Novartis Main Business Overview
13.10.5 Novartis Latest Developments
13.11 Merck
13.11.1 Merck Company Information
13.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Merck Main Business Overview
13.11.5 Merck Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Alpha-Blocker
Table 4. Major Players of PhosphodiesteraseType-5 Inhibitors
Table 5. Major Players of Others
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales byType (2020-2025) & (M Units)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share byType (2020-2025)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue byType (2020-2025) & ($ million)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share byType (2020-2025)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price byType (2020-2025) & (US$/Unit)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale by Application (2020-2025) & (M Units)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Market Share by Application (2020-2025)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2020-2025) & ($ million)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2020-2025)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2020-2025) & (US$/Unit)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025) & (M Units)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2025)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2025)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company (2020-2025) & (US$/Unit)
Table 21. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Producing Area Distribution and Sales Area
Table 22. Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
Table 23. Benign Prostatic Hyperplasia (BPH) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Region (2020-2025) & (M Units)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Geographic Region (2020-2025)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country/Region (2020-2025) & (M Units)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country/Region (2020-2025)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) & (M Units)
Table 35. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2020-2025)
Table 36. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales byType (2020-2025) & (M Units)
Table 38. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 39. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2020-2025) & (M Units)
Table 40. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2020-2025)
Table 41. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales byType (2020-2025) & (M Units)
Table 43. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 44. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) & (M Units)
Table 45. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales byType (2020-2025) & (M Units)
Table 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 48. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) & (M Units)
Table 49. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales byType (2020-2025) & (M Units)
Table 51. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 52. Key Market Drivers & Growth Opportunities of Benign Prostatic Hyperplasia (BPH) Drugs
Table 53. Key Market Challenges & Risks of Benign Prostatic Hyperplasia (BPH) Drugs
Table 54. Key IndustryTrends of Benign Prostatic Hyperplasia (BPH) Drugs
Table 55. Benign Prostatic Hyperplasia (BPH) Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 58. Benign Prostatic Hyperplasia (BPH) Drugs Customer List
Table 59. Global Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast by Region (2026-2031) & (M Units)
Table 60. Global Benign Prostatic Hyperplasia (BPH) Drugs RevenueForecast by Region (2026-2031) & ($ millions)
Table 61. Americas Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast by Country (2026-2031) & (M Units)
Table 62. Americas Benign Prostatic Hyperplasia (BPH) Drugs Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 63. APAC Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast by Region (2026-2031) & (M Units)
Table 64. APAC Benign Prostatic Hyperplasia (BPH) Drugs Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 65. Europe Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast by Country (2026-2031) & (M Units)
Table 66. Europe Benign Prostatic Hyperplasia (BPH) Drugs RevenueForecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast by Country (2026-2031) & (M Units)
Table 68. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Global Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast byType (2026-2031) & (M Units)
Table 70. Global Benign Prostatic Hyperplasia (BPH) Drugs RevenueForecast byType (2026-2031) & ($ millions)
Table 71. Global Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast by Application (2026-2031) & (M Units)
Table 72. Global Benign Prostatic Hyperplasia (BPH) Drugs RevenueForecast by Application (2026-2031) & ($ millions)
Table 73. Eli Lilly Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 75. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 76. Eli Lilly Main Business
Table 77. Eli Lilly Latest Developments
Table 78. GlaxoSmithKline Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 80. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. GlaxoSmithKline Main Business
Table 82. GlaxoSmithKline Latest Developments
Table 83. Astellas Pharma Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 85. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 86. Astellas Pharma Main Business
Table 87. Astellas Pharma Latest Developments
Table 88. Sanofi Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 90. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 91. Sanofi Main Business
Table 92. Sanofi Latest Developments
Table 93. Pfizer Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 95. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 96. Pfizer Main Business
Table 97. Pfizer Latest Developments
Table 98. Abbott Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 100. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 101. Abbott Main Business
Table 102. Abbott Latest Developments
Table 103. Allergan Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 105. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 106. Allergan Main Business
Table 107. Allergan Latest Developments
Table 108.TEVA Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109.TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 110.TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 111.TEVA Main Business
Table 112.TEVA Latest Developments
Table 113. Mylan Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 115. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 116. Mylan Main Business
Table 117. Mylan Latest Developments
Table 118. Novartis Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 120. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 121. Novartis Main Business
Table 122. Novartis Latest Developments
Table 123. Merck Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 125. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 126. Merck Main Business
Table 127. Merck Latest Developments
LIST OFFIGURES
Figure 1. Picture of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 2. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2020-2031 (M Units)
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country/Region (2024)
Figure 10. Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Alpha-Blocker
Figure 12. Product Picture of PhosphodiesteraseType-5 Inhibitors
Figure 13. Product Picture of Others
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share byType in 2025
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share byType (2020-2025)
Figure 16. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Hospitals
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Hospitals (2020-2025) & (M Units)
Figure 18. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Drugstores
Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Drugstores (2020-2025) & (M Units)
Figure 20. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Others
Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Others (2020-2025) & (M Units)
Figure 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Market Share by Application (2024)
Figure 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application in 2025
Figure 24. Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company in 2025 (M Units)
Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2025
Figure 26. Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company in 2025 ($ millions)
Figure 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company in 2025
Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales 2020-2025 (M Units)
Figure 31. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2020-2025 ($ millions)
Figure 32. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales 2020-2025 (M Units)
Figure 33. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2020-2025 ($ millions)
Figure 34. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales 2020-2025 (M Units)
Figure 35. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales 2020-2025 (M Units)
Figure 37. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2020-2025 ($ millions)
Figure 38. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2025
Figure 39. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2025)
Figure 40. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share byType (2020-2025)
Figure 41. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Figure 42. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2025
Figure 47. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2020-2025)
Figure 48. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share byType (2020-2025)
Figure 49. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Figure 50. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. ChinaTaiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2025
Figure 58. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2025)
Figure 59. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share byType (2020-2025)
Figure 60. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Figure 61. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 62.France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share byType (2020-2025)
Figure 68. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Figure 69. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72.Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in 2025
Figure 75. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 76. Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 77. Channels of Distribution
Figure 78. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales MarketForecast by Region (2026-2031)
Figure 79. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market ShareForecast by Region (2026-2031)
Figure 80. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market ShareForecast byType (2026-2031)
Figure 81. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market ShareForecast byType (2026-2031)
Figure 82. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market ShareForecast by Application (2026-2031)
Figure 83. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Country/Region, 2020, 2024 & 2031
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
2.2.1 Alpha-Blocker
2.2.2 Phosphodiesterase Type-5 Inhibitors
2.2.3 Others
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2020-2025)
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Drugstores
2.4.3 Others
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
2.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2025)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company
3.4 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Location Distribution
3.4.2 Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
4.4 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
4.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
4.6 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
5 AMERICAS
5.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025)
5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025)
5.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
5.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2020-2025)
6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2020-2025)
6.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
6.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Country
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025)
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs by Country
8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
10.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
10.4 Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
11.3 Benign Prostatic Hyperplasia (BPH) Drugs Customer
12 WORLD FORECAST REVIEW FOR BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY GEOGRAPHIC REGION
12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Region
12.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Region (2026-2031)
12.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type (2026-2031)
12.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Eli Lilly
13.1.1 Eli Lilly Company Information
13.1.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Eli Lilly Main Business Overview
13.1.5 Eli Lilly Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Astellas Pharma
13.3.1 Astellas Pharma Company Information
13.3.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Astellas Pharma Main Business Overview
13.3.5 Astellas Pharma Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 Abbott
13.6.1 Abbott Company Information
13.6.2 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Abbott Main Business Overview
13.6.5 Abbott Latest Developments
13.7 Allergan
13.7.1 Allergan Company Information
13.7.2 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Allergan Main Business Overview
13.7.5 Allergan Latest Developments
13.8 TEVA
13.8.1 TEVA Company Information
13.8.2 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 TEVA Main Business Overview
13.8.5 TEVA Latest Developments
13.9 Mylan
13.9.1 Mylan Company Information
13.9.2 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Mylan Main Business Overview
13.9.5 Mylan Latest Developments
13.10 Novartis
13.10.1 Novartis Company Information
13.10.2 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Novartis Main Business Overview
13.10.5 Novartis Latest Developments
13.11 Merck
13.11.1 Merck Company Information
13.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
13.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Merck Main Business Overview
13.11.5 Merck Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Alpha-Blocker
Table 4. Major Players of PhosphodiesteraseType-5 Inhibitors
Table 5. Major Players of Others
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales byType (2020-2025) & (M Units)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share byType (2020-2025)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue byType (2020-2025) & ($ million)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share byType (2020-2025)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price byType (2020-2025) & (US$/Unit)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale by Application (2020-2025) & (M Units)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Market Share by Application (2020-2025)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2020-2025) & ($ million)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2020-2025)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2020-2025) & (US$/Unit)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025) & (M Units)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2025)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2025)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company (2020-2025) & (US$/Unit)
Table 21. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Producing Area Distribution and Sales Area
Table 22. Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
Table 23. Benign Prostatic Hyperplasia (BPH) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Region (2020-2025) & (M Units)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Geographic Region (2020-2025)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country/Region (2020-2025) & (M Units)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country/Region (2020-2025)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) & (M Units)
Table 35. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2020-2025)
Table 36. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales byType (2020-2025) & (M Units)
Table 38. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 39. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2020-2025) & (M Units)
Table 40. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2020-2025)
Table 41. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales byType (2020-2025) & (M Units)
Table 43. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 44. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) & (M Units)
Table 45. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales byType (2020-2025) & (M Units)
Table 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 48. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) & (M Units)
Table 49. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales byType (2020-2025) & (M Units)
Table 51. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 52. Key Market Drivers & Growth Opportunities of Benign Prostatic Hyperplasia (BPH) Drugs
Table 53. Key Market Challenges & Risks of Benign Prostatic Hyperplasia (BPH) Drugs
Table 54. Key IndustryTrends of Benign Prostatic Hyperplasia (BPH) Drugs
Table 55. Benign Prostatic Hyperplasia (BPH) Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 58. Benign Prostatic Hyperplasia (BPH) Drugs Customer List
Table 59. Global Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast by Region (2026-2031) & (M Units)
Table 60. Global Benign Prostatic Hyperplasia (BPH) Drugs RevenueForecast by Region (2026-2031) & ($ millions)
Table 61. Americas Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast by Country (2026-2031) & (M Units)
Table 62. Americas Benign Prostatic Hyperplasia (BPH) Drugs Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 63. APAC Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast by Region (2026-2031) & (M Units)
Table 64. APAC Benign Prostatic Hyperplasia (BPH) Drugs Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 65. Europe Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast by Country (2026-2031) & (M Units)
Table 66. Europe Benign Prostatic Hyperplasia (BPH) Drugs RevenueForecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast by Country (2026-2031) & (M Units)
Table 68. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Global Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast byType (2026-2031) & (M Units)
Table 70. Global Benign Prostatic Hyperplasia (BPH) Drugs RevenueForecast byType (2026-2031) & ($ millions)
Table 71. Global Benign Prostatic Hyperplasia (BPH) Drugs SalesForecast by Application (2026-2031) & (M Units)
Table 72. Global Benign Prostatic Hyperplasia (BPH) Drugs RevenueForecast by Application (2026-2031) & ($ millions)
Table 73. Eli Lilly Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 75. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 76. Eli Lilly Main Business
Table 77. Eli Lilly Latest Developments
Table 78. GlaxoSmithKline Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 80. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. GlaxoSmithKline Main Business
Table 82. GlaxoSmithKline Latest Developments
Table 83. Astellas Pharma Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 85. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 86. Astellas Pharma Main Business
Table 87. Astellas Pharma Latest Developments
Table 88. Sanofi Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 90. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 91. Sanofi Main Business
Table 92. Sanofi Latest Developments
Table 93. Pfizer Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 95. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 96. Pfizer Main Business
Table 97. Pfizer Latest Developments
Table 98. Abbott Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 100. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 101. Abbott Main Business
Table 102. Abbott Latest Developments
Table 103. Allergan Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 105. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 106. Allergan Main Business
Table 107. Allergan Latest Developments
Table 108.TEVA Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109.TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 110.TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 111.TEVA Main Business
Table 112.TEVA Latest Developments
Table 113. Mylan Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 115. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 116. Mylan Main Business
Table 117. Mylan Latest Developments
Table 118. Novartis Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 120. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 121. Novartis Main Business
Table 122. Novartis Latest Developments
Table 123. Merck Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
Table 125. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 126. Merck Main Business
Table 127. Merck Latest Developments
LIST OFFIGURES
Figure 1. Picture of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 2. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2020-2031 (M Units)
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country/Region (2024)
Figure 10. Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Alpha-Blocker
Figure 12. Product Picture of PhosphodiesteraseType-5 Inhibitors
Figure 13. Product Picture of Others
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share byType in 2025
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share byType (2020-2025)
Figure 16. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Hospitals
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Hospitals (2020-2025) & (M Units)
Figure 18. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Drugstores
Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Drugstores (2020-2025) & (M Units)
Figure 20. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Others
Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Others (2020-2025) & (M Units)
Figure 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Market Share by Application (2024)
Figure 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application in 2025
Figure 24. Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company in 2025 (M Units)
Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2025
Figure 26. Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company in 2025 ($ millions)
Figure 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company in 2025
Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales 2020-2025 (M Units)
Figure 31. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2020-2025 ($ millions)
Figure 32. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales 2020-2025 (M Units)
Figure 33. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2020-2025 ($ millions)
Figure 34. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales 2020-2025 (M Units)
Figure 35. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales 2020-2025 (M Units)
Figure 37. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2020-2025 ($ millions)
Figure 38. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2025
Figure 39. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2025)
Figure 40. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share byType (2020-2025)
Figure 41. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Figure 42. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2025
Figure 47. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2020-2025)
Figure 48. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share byType (2020-2025)
Figure 49. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Figure 50. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. ChinaTaiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2025
Figure 58. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2025)
Figure 59. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share byType (2020-2025)
Figure 60. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Figure 61. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 62.France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share byType (2020-2025)
Figure 68. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Figure 69. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72.Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in 2025
Figure 75. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 76. Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 77. Channels of Distribution
Figure 78. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales MarketForecast by Region (2026-2031)
Figure 79. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market ShareForecast by Region (2026-2031)
Figure 80. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market ShareForecast byType (2026-2031)
Figure 81. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market ShareForecast byType (2026-2031)
Figure 82. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market ShareForecast by Application (2026-2031)
Figure 83. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market ShareForecast by Application (2026-2031)
More Publications
Global Disposable Hemoperfusion Market Growth 2025-2031
US$ 3,660.00
March 2025
104 pages
Global Chinese Medicine Injection Market Growth 2024-2030
US$ 3,660.00
June 2024
110 pages
Global Animal Infusion Pump Market Growth 2023-2029
US$ 3,660.00
March 2023
108 pages
Global Minimally Invasive Female Urinary Incontinence Devices Market Growth 2023-2029
US$ 3,660.00
February 2023
113 pages
Global Mupirocin Calcium 2% Cream Market Growth 2023-2029
US$ 3,660.00
February 2023
105 pages
